Chiara Borsari

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 132 citations · Full text

Chemoprevention Strategy, Immunology, Clinical Candidate +19

Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders

Denise Rageot, Thomas Bohnacker, Anna Melone et al. · Journal of Medicinal Chemistry · 2018 · 83 citations · Full text

Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity

F. Di Pisa, Giacomo Landi, Lucia Dello Iacono et al. · Molecules · 2017 · 64 citations · Full text

Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs

Chiara Borsari, Rosaria Luciani, Cecilia Pozzi et al. · Journal of Medicinal Chemistry · 2016 · 55 citations · Full text

(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase

Denise Rageot, Thomas Bohnacker, Erhan Keleş et al. · Journal of Medicinal Chemistry · 2019 · 54 citations · Full text

Compound 6, Brain Penetration, Cellular Pharmacology +25